Biotest AG / Key word(s): Profit Warning
Biotest AG: Reduction of guidance
08-Dec-2021 / 19:23 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Dreieich, 08 Dezember 2021. Due to the changing market environment for the plasmatic coagulation factor VIII, the Supervisory Board of Biotest Aktiengesellschaft decided in its meeting today that Biotest will only produce factor VIII in a sales-correlated manner in the future. Biotest will therefore make depreciations on existing raw material in the amount of approximately € 38 – 45 million.
The exact financial impact of the one-time effect is currently still being determined. As a precautionary measure, Biotest AG is reducing its EBIT guidance for 2021 from € – 5 to – 10 million to approximately € – 43 to – 55 million.
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com
Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201
|Phone:||0 61 03 – 8 01-0|
|Fax:||0 61 03 – 8 01-150|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1255711|
|End of Announcement||DGAP News Service|